Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.
How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Eli Lilly and Company's score of 63 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Eli Lilly and Company reported total greenhouse gas emissions of approximately 5,134,500,000 kg CO2e across all scopes. This includes 182,000,000 kg CO2e from Scope 1 (direct emissions), 345,000,000 kg CO2e from Scope 2 (indirect emissions from energy), and a significant 5,134,500,000 kg CO2e from Scope 3 (indirect emissions from the value chain). Eli Lilly has made notable strides in reducing its carbon footprint, achieving a 26% reduction in absolute emissions from 2012 to 2020. More recently, from 2020 to 2023, the company has maintained this momentum with another 26% reduction in its own operations, alongside a 3% year-on-year reduction from 2022. Looking ahead, Eli Lilly is committed to becoming carbon neutral in its operations (Scope 1 and 2 emissions) by 2030. The company is also focused on enhancing its full value-chain emissions reporting and has set a legally binding commitment to reduce emissions in the UK to net zero by 2050. These initiatives reflect Eli Lilly's dedication to driving greenhouse gas emissions reductions throughout its operations and supply chain.
Access structured emissions data, company-specific emission factors, and source documents
2007 | 2010 | 2011 | 2012 | 2013 | 2014 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 527,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 14,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eli Lilly and Company is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.